Department of Pharmacy Administration, School of Pharmacy, University of Mississippi, University, MS 38677, USA.
Department of Pharmacy Administration, School of Pharmacy, University of Mississippi, University, MS 38677, USA.
Vaccine. 2020 Feb 18;38(8):2051-2057. doi: 10.1016/j.vaccine.2019.12.030. Epub 2020 Jan 21.
To identify factors associated with Human Papillomavirus (HPV) vaccine series completion among vaccine initiators in Mississippi Medicaid.
2013-2018 Mississippi Medicaid administrative claims data were analyzed. Female and male beneficiaries aged 9 to 26 years who initiated HPV vaccination in the identification period were assessed for completion of age-appropriate number of recommended doses within a period of 12 months. Sex-stratified multivariable logistic regression was used to examine factors associated with HPV vaccine series completion in the study sample.
A total of 18,110 female and 18,186 male beneficiaries initiated HPV vaccine between January 1, 2014 and June 30, 2017. Most of the initiators belonged to ages 11 to 12 years, African American race, managed care plans and Central Mississippi public health region. The vaccine series completion rate was 34% for females and 30% for males. Younger age at initiation was a significant predictor of vaccine series completion in both sexes. Specifically, initiators in age groups 9 to 10 and 11 to 12 years, respectively, had greater odds of completion, while initiators aged 15 to 26 years had lower odds of completion compared to initiators aged 13 to 14 years. Female and male beneficiaries in managed care plans (vs. fee-for-service) and of African American race (vs. Caucasians) had lower odds of completing the vaccine series. Female and male beneficiaries who initiated HPV vaccine series with a pediatrician had the highest completion rates.
HPV vaccination series completion rate in Mississippi Medicaid was suboptimal despite the high HPV-related cancer incidence in the state. HPV vaccine series completion is influenced by various sociodemographic factors. There is a need for robust education and public health programs to encourage completion of recommended doses.
确定密西西比州医疗补助计划中 HPV 疫苗接种启动者系列接种完成的相关因素。
分析了 2013 年至 2018 年密西西比州医疗补助管理索赔数据。在确定期间内，9 至 26 岁的女性和男性受益人均接受了 HPV 疫苗接种，评估其在 12 个月内完成了相应年龄推荐剂量的比例。采用性别分层多变量逻辑回归分析研究样本中 HPV 疫苗系列接种完成的相关因素。
共有 18110 名女性和 18186 名男性受益于 2014 年 1 月 1 日至 2017 年 6 月 30 日期间启动了 HPV 疫苗接种。大多数启动者属于 11 至 12 岁、非裔美国人、管理式医疗计划和密西西比州中部公共卫生区。女性疫苗系列接种完成率为 34%，男性为 30%。启动疫苗接种的年龄较小是两性疫苗系列接种完成的重要预测因素。具体而言，年龄分别为 9 至 10 岁和 11 至 12 岁的启动者完成疫苗接种的可能性更大，而年龄在 15 至 26 岁的启动者与年龄在 13 至 14 岁的启动者相比，完成疫苗接种的可能性更低。管理式医疗计划（相对于按服务收费）和非裔美国人（相对于白人）的女性和男性受益人的疫苗系列接种完成率较低。与儿科医生启动 HPV 疫苗系列接种的女性和男性受益人的完成率最高。
尽管该州 HPV 相关癌症发病率较高，但密西西比州医疗补助计划中的 HPV 疫苗接种系列接种完成率并不理想。HPV 疫苗系列接种完成情况受到各种社会人口因素的影响。需要强有力的教育和公共卫生计划来鼓励完成推荐剂量的接种。
